Eli Lilly CDR (CAD Hedged)
- Country
- đşđ¸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT06916078
- Locations
- đşđ¸
Clinical Pharmacology of Miami, Miami, Florida, United States
đşđ¸Orlando Clinical Research Center, Orlando, Florida, United States
đşđ¸American Research Corporation at Texas Liver Institute, San Antonio, Texas, United States
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
- Conditions
- Type 1 DiabetesObesityOverweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 905
- Registration Number
- NCT06914895
- Locations
- đşđ¸
Sansum Diabetes Research Institute, Goleta, California, United States
đşđ¸Sansum Diabetes Research Institute, Goleta, California, United States
đşđ¸Care Access - Santa Clarita, Santa Clarita, California, United States
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: [14C]-STX-478
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-05-25
- Target Recruit Count
- 8
- Registration Number
- NCT06901336
- Locations
- đşđ¸
Pharmaron Clinical Pharmacology Center Inc, Baltimore, Maryland, United States
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT06901349
- Locations
- đşđ¸
Yuma Clinical Trials, Yuma, Arizona, United States
đşđ¸Orange County Research Center, Lake Forest, California, United States
đşđ¸Healthy Brain Clinic, Long Beach, California, United States
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT06897475
- Locations
- đşđ¸
Helios Clinical Research - Phoenix, Phoenix, Arizona, United States
đşđ¸Wolverine Clinical Trials, Santa Ana, California, United States
đşđ¸Renstar Medical Research, Ocala, Florida, United States
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT06890611
- Locations
- đşđ¸
Fortrea Clinical Research Unit, Dallas, Texas, United States
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 700
- Registration Number
- NCT06890598
- Locations
- đşđ¸
University of Alabama at Birmingham, Birmingham, Alabama, United States
đşđ¸Clearview Cancer Institute, Huntsville, Alabama, United States
đşđ¸The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 279
- Registration Number
- NCT06876662
- Locations
- đşđ¸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
đşđ¸Florida Cancer Specialists, Sarasota, Florida, United States
đşđ¸The Emory Clinic, Atlanta, Georgia, United States
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Conditions
- Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 279
- Registration Number
- NCT06876649
- Locations
- đ¨đł
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
đ¨đłHarbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
đ¨đłUnion Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
- Conditions
- HealthyType 2 Diabetes Mellitus (T2D)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT06869018
- Locations
- đŻđľ
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
đŻđľP-One Clinic, Hachioji, Tokyo, Japan
đŻđľClinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan